Endocrine Control of Food Intake Flashcards

1
Q

What two factors have to be balanced in body weight homeostasis?

A

Food intake

Energy expenditure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What controls body weight homeostasis?

A

Hypothalamus

  • All the inputs come into the hypothalamus
  • The hypothalamus determines your appetite
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which areas of the hypothalamus are important in regulating food intake?

A
  • Arcuate nucleus
    • The arcuate nucleus is like a switchboard
    • It receives signals from the GI tract
    • It has different neuronal populations which regulate appetite based on the signals received
    • It is the key brain area involved in the regulation of food intake
      • This is the main one you need to know
  • Lateral hypothalamus
    • Also known as lateral hypothalamic area
    • Feeding centre - when stimulated, it causes the sensation of hunger
  • Ventromedial hypothalamus
    • Also known as ventromedial nucleus
    • Satiety centre - when stimulated, it causes the sensation of fullness

NOTES:

  • Nucleus = group of cell bodies in the CNS
  • There are two of each structure - one on each side
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Give some characteristics of the arcuate nucleus and explain how this helps with its function?

A

It is a circumventricular organ - so it has an incomplete blood-brain barrier

  • This means that the arcuate nucleus is exposed to peripheral hormones
  • Allows it to integrate peripheral and central feeding inputs
    • Central - i.e. inputs from other brain regions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the two neuronal populations in the arcuate nucleus?

A
  • AgRP/NPY = increase appetite
  • POMC = decrease appetite

Both sets of neurons extend to other hypothalamic and extra- hypothalamic regions

  • Essentially each neuronal population produces these peptides which act as signalling molecules to other neurones
  • One population co-expresses the neuropeptides AgRP and NPY - i.e. produce both
    • These neurones are orexigenic (stimulates appetite)
  • The other population produces POMC
    • There neurones are anorexigenic (inhibits appetite)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the main way the stomach detects whether your stomach is empty or full?

A

If you miss a meal, mechanoreceptors in the stomach detect that your stomach is empty.

This triggers vagal nerve firing to the solitary nucleus in the medulla.

The solitary nucleus then stimulates nerves going up to the arcuate nucleus in the hypothalamus

The arcuate nucleus:

  • Activates the lateral hypothalamic areas through these orexigenic neurons which coexpress NPY and AgRP
  • Inhibits the activation of the ventromedial nuclei by preventing the release of POMC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe how the melanocortin system works.

A

After you’ve eaten:

  • POMC is broken down to α-MSH which is then released
  • α-MSH is an endogenous agonist of the melanocortin 4 receptor (MC4R)
  • Stimulation by α-MSH inhibits food intake - i.e. this makes you feel full
  • This also just happens normally to stop you from constanly feeling hungry

When you need to eat:

  • There will be an increase in AgRP/NPY neuronal activity so more AgRP is released
  • AgRP is an endogenous antagonist of MC4R
  • AgRP will block the MC4R receptor - block the inhibitory signal of a-MSH
  • This stimulates food intake - i.e. this makes you hungry

MCR4 is present in the paraventricular nucleus

NOTE: This is not the only mechanism involved in appetite regulation as you also have the feeding centre (lateral hypothalamus) and satiety centre (ventromedial hypothalamus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

State some CNS mutations that affect this system and can cause obesity.

A
  • POMC deficiency
    • Causes morbid obesity
    • Associated with red hair and pale skin due to lack of MSH and therefore melanin
    • no ACTH, so HPA-axis is lost
  • MC4R mutation
    • Causes morbid obesity
  • There are no known Agrp or NPY mutations

Morbid obesity because:

  • POMC deficiency → no α-MSH released to bind to MC4R
  • MC4R mutation → receptor not functioning as it should
  • Lack of MC4R activation or functionality prevents appetite inhibition → ravenous eating due to insatiable hunger → obesity

Mutations not responsible for the prevalence of obesity but these clinical examples have been useful to explain signalling (i.e. how signalling in the CNS regulates food intake)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is leptin?

A
  • 167 amino acid hormone
  • Produced by adipocytes and signals to the brain, telling it how much fat there is in storage
    • Leptin circulates in plasma in concentrations proportional to fat mass
      • Low levels when body fat is low
      • High levels when body fat is high
  • Central or peripheral administration decreases food intake and increases thermogenesis
    • Activates POMC and inhibits NPY/AgRP neurons
      • This acts to decrease appetite - so leptin acts as a satiety hormone
      • Leptin levels increase slightly at night which is responsible for the lack of hunger when you’re sleeping
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the main function of leptin in the body?

A

Leptin is mainly an anti-starvation hormone rather than an anti-obesity hormone

  • Presence of leptin tells the brain that one has sufficient fat reserves for normal functioning but high leptin has little effect
    • Leptin levels which are high will make you feel full to an extent so you are not constantly hungry
    • But extremely high leptin won’t have any more of an effect - you won’t stop eating completely
  • So if a lack of leptin signalling indicates to the brain that you are starving
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the features of the leptin deficiency ob/ob mouse?

A

Recessive mutation

  • Profoundly obese
    • Leptin acts as a satiety hormone
    • Lack of leptin → excessive hunger and eating (hyperphagia) → obesity
  • Diabetic
  • Infertile/sterile
    • Lack of leptin signalling to brain shuts down reproductive axis
  • Stunted linear growth
    • Energy-consuming process
  • Decreased body temperature
    • Lack of leptin → decreased thermogenesis
  • Decreased energy expenditure
    • If body is in starvation, then you would want to preserve more energy
  • Decreased immune function
    • Immune system is energy-consuming

Aside from obesity and diabetes, similar abnormalities to starved animals - essentially leptin deficiency signals body to go into starvation mode

In bold - main effects of leptin deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What leptin-related issue do most obese people have?

A
  • Most obese people have high leptin
    • Because leptin circulates in plasma in concentrations proportional to fat mass
  • Therefore, obesity is due to leptin resistance
    • i.e. The hormone is present but doesn’t signal effectively
  • This means that leptin is ineffective as a weight control drug

REMEMBER: However, people with leptin deficiency (rare) will respond well to leptin therapy as they have never seen it before so there is no resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Why won’t people with leptin deficiency go through puberty?

A
  • Leptin has a permissive effect on GnRH release
  • Without GnRH release, you will not get sufficient LH and FSH release to cause puberty
    • If you inject a leptin deficient person with leptin, you see LH pulsatiility restored
  • This is also the reason why people who are severely underweight get secondary amenorrhoea
    • You can make these people start having periods again by giving leptin - it gives the illusion of having sufficient body fat
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the central effects of insulin.

A
  • Insulin circulates at levels proportional to body fat
    • This may be partly due to the fact that fat people are more likely to be insulin resistant so more insulin is needed
    • It is generally accepted that lipids play a role in insulin secretion signaling, but the precise pathways and molecules involved in the process remains uncertain
  • There are insulin receptors in the hypothalamus
  • Insulin signals in a similar way to leptin in the sense that central administration of insulin reduces food intake
  • Insulin can cross the BBB to have certain effects:
    • Chronically - reduce body fat
    • Acutely - if you have a big glucose load, you should suppress having more sugar
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is ghrelin? Give some characteristics of ghrelin.

A
  • Hunger hormone
  • Gastric = released by stomach
  • Peptide
    • 28 AAs long
    • Converted to the active form by Ghrelin O-Acyltransferase (GOAT)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe how ghrelin levels change throughout the day.

A

Ghrelin levels drop after every meal and then slowly rises (before the next meal)

  • It is high in the morning and then goes down after breakfast and rises again until lunch

NOTE:

  • This pattern works when you’re awake
  • But ghrelin levels reduce during sleep because you don’t need as much energy and therefore food intake when alseep
17
Q

What effect does ghrelin in the CNS?

A

Directly modulates neurones in the arcuate nucleus to increase appetite:

  • Stimulates Agrp/NPY neurones
  • Inhibits POMC neurones

Ghrelin increases food intake in humans - if you get someone who has just had a meal, you can trick them into feeling hungry by giving ghrelin

18
Q

Where is both PYY and GLP-1 secreted from?

A

L-cells

  • Located along the GI epithelium
    • Small intestine and large intestine
19
Q

Describe the structure of PYY.

A
  • PYY has 36 amino acids
  • But most common circulating form is PYY3-36
    • Has had its tyrosine-1 and proline-2 removed from the N-
    • Changes 3D conformation of PYY - impacts receptor selectivity
    • Conversion of PPY to PPY3-36 is carried out by the enzyme di-peptidyl peptidase IV (DP4)
20
Q

How is PYY released?

A

Peptide YY (PYY) is released post-prandially (after a meal)

  • The amount of PYY released is dependent on the size of the meal
21
Q

What effect does PYY3-36 have in the CNS?

A

Directly modulates neurones in the arcuate nucleus to decrease appetite:

  • Inhibits NPY release
    • NPY doesn’t directly antagonise the MC4R, but has effects on other parts of the plain to increase appetite
  • Stimulates POMC neurons

PYY3-36 and ghrelin have opposite effects on the arcuate nucleus

  • So PYY3-36 can reduce the appetite of hungry people
22
Q

What is GLP-1 and what gene codes for it?

A

GLP-1 = Glucagon-Like Peptide 1

  • Coded for by pre-proglucagon gene
23
Q

How is GLP-1 released?

A

Post-prandially (after a meal)

24
Q

What are the effects of GLP-1?

A
  • Important role in the incretin effect
  • Decreases food intake
25
Q

What is the incretin effect?

A

Oral glucose dose produces a much bigger rise in insulin than the same dose of glucose given intravenously

  • This is because glucose travelling in the GI tract stimulates the release of GLP-1 release from L-cells
  • GLP-1 stimulates insulin release
  • So essentially, you get glucose-induced insulin release potentiated (enhanced) by GLP-1
26
Q

What are GLP-1 based drugs used to treat?

A

Diabetes mellitus

  • GLP-1 agonists/DPPD-4 inhibitors helps insulin release
  • Added benefit of appetite suppression
    • Therefore the drug also helps counteract obesity
    • Weight loss is an effective diabetes treatment
  • Reduced risk of hypoglycaemia
    • GLP-1 only stimulates glucose-induced insulin release
    • This it means that it only stimulates insulin release when it’s needed
      • i.e. After a meal which will cause plasma glucose levels to rise
27
Q

Describe the degradation of GLP-1.

A
  • It is rapidly broken down (inactivated) by dipeptidyl peptidase-4 (DPPG-4)
  • It has a half-life of approximately 1 minute
28
Q

Give an example of a GLP-1 based drug.

A

Saxenda

  • Long-acting GLP-1 receptor agonist (liraglutide) from Novo Nordisk
  • The structure of GLP-1 has been tweaked so it is more resistant to degradation
  • It also has a fatty acid group attached which stops it from being cleared from the circulation giving it a much longer half-life
    • FA chain makes it non-polar which is harder to excrete in the urine
    • Lipid soluble substances not actively excreted and they can just diffuse back into the blood through the lipid bilayers of the tubular and endothelial cells
  • Saxenda has recently been approved by the FDA and EMEA as a treatment for diabetes and obesity
    • But in order to treat obesity and get fairly decent weight loss you have to double the dose used for treating T2DM
29
Q

What are the 3 types of satiety action by gut hormones?

A

Satiety hormones: PYY and GLP-1

  • Post-prandial
    • Reduces food intake following a meal
  • Chronic
    • In gut disease, chronic elevation of the hormones of suppresses appetite
    • The idea behind this is probably to reduce the stress on the gut
  • Acute nausea
    • In response to toxin ingestion
    • You get very high levels of the hormones acutely
    • Idea behind this is body signalling you shouldn’t eat any more of that substance and maybe vomit to empty it out of your system
30
Q

What is the problem with satiety gut hormones as a drug target (i.e. basing a drug on the hormones)?

A
  • These hormones have short half lives
  • Therefore if you inject the hormone, you will get a big, transient increase in drug concentration and then a relatively rapid drop
    • High levels of the drug will cause nausea
    • At low levels the drug is not really effective
    • Only small period of time when the drug is in the effective part of the response curve
  • There is a relatively narrow range of drug concentration at which the drug wil be effective
    • Effective in reducing appetite, increasing insulin secretion
  • You want to mofidy these molecules to give them better pharmacokinetic profiles
    • You want the plasma drug concentration to increase enugh to get to the effective range, but not too much that it causes nausea
      • So the dose should be high enough but not too high
    • And you want the drug concentration to stay within the effective range for a long time
      • So you want to increase half-life
  • The structure of saxenda means it has a longer half-life than GLP-1
    • However, the main side effect of saxenda is nausea
31
Q

State some comorbidities associated with obesity.

A
32
Q

What is the thrifty gene hypothesis?

A

It was evolutionarily sensible to put on extra weight

  • Thin people didn’t put on much weight and didn’t carry excess fat during the times when food was scarce
  • So they didn’t survive familes and didn’t pass their genes on (to modern humans)

The specific genes that were selected acted to increase metabolic efficiency and fat storage

  • In the context of plentiful food and little exercise these genes predispose their carriers to obesity and diabetes

Evidence:

  • Populations historically prone to starvation become the most obese when exposed to Western diet and sedentary life-style
    • e.g. Pima Indians, Pacific Islanders
33
Q

What is the adaptive drift hypothesis?

A

There use to be a normal distribution in terms of body weight:

  • The fat would be eaten by predators
  • The thin would die in times of famine

But then humans learned to defend against predators

Thus obesity not selected against.

  • Putting on body fat became a neutral change leading to genetic drift
  • Neutral change in the sense that this change was neither beneficial nor detrimental
  • Genetic drift as those genes which enabled humans to put on body fat became more prevalent in the population
  • Though at the time, humans were unlikely to put on much weight due to limited food availability
  • In the current context, the inheritors of these genes become obese